Author: Karl-Walter Bock
Publisher: Springer
ISBN:
Category : Medical
Languages : en
Pages : 344

View

Book Description

Author: National Library of Medicine (U.S.)
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 558

View

Book Description
First multi-year cumulation covers six years: 1965-70.

Author: Wen Xie
Publisher: Academic Press
ISBN: 0128029633
Category : Medical
Languages : en
Pages : 296

View

Book Description
Drug Metabolism in Diseases is a comprehensive reference devoted to the current state of research on the impact of various disease states on drug metabolism. The book contains valuable insights into mechanistic effects and examples of how to accurately predict drug metabolism during these different pathophysiological states. Each chapter clearly presents the effects of changes in drug metabolism and drug transporters on pharmacokinetics and disposition. This is a unique and useful approach for all those involved in drug discovery and development, and for clinicians and researchers in drug metabolism, pharmacology, and clinical pharmacology. - Written and edited by leaders in drug metabolism from academia and industry - Covers important topics, such as pharmacogenomics, drug metabolism in transplant patients, xenobiotic receptors, drug metabolism in geriatric and pediatric populations, and more - Highlights topics of importance in drug discovery and development, and for safe and effective drug use in the clinic

Author: Georg Hennemann
Publisher: Marcel Dekker
ISBN:
Category : Medical
Languages : en
Pages : 656

View

Book Description

Author: Philip Wexler
Publisher: Academic Press
ISBN: 0127447709
Category : Medical
Languages : en
Pages : 953

View

Book Description
History: -- K.D. Watson, P. Wexler, and J. Everitt. -- Highlights in the History of Toxicology. -- Selected References in the History of Toxicology. -- A Historical Perspective of Toxicology Information Systems. -- Books and Special Documents: -- G.L. Kennedy, Jr., P. Wexler, N.S. Selzer, and L.A. Malley. -- General Texts. -- Analytical Toxicology. -- Animals in Research. -- Biomonitoring/Biomarkers. -- Biotechnology. -- Biotoxins. -- Cancer. -- Chemical Compendia. -- Chemical--Cosmetics and Other Consumer. -- Products. -- Chemical--Drugs. -- Chemical--Dust and Fibers. -- Chemical--Metals. -- Chemicals--Pesticides -- Chemicals--Solvents. -- Chemical--Selected Chemicals. -- Clinical Toxicology. -- Developmental and Reproductive Toxicology. -- Environmental Toxicology--General. -- Environmental Toxicology-- Aquatic. -- Environmental Toxicology--Atmospheric. -- Environmental Toxicology--Hazardous Waste. -- Environmental Toxicology--Terrestrial. -- Environmental Toxicology--Wildlife. -- Ep ...

Author: Takamatsu no Miya Hi Gan Kenkyū Kikin. International Symposium
Publisher: Taylor & Francis
ISBN: 9780748400379
Category : Medical
Languages : en
Pages : 394

View

Book Description
The 21st International Symposium of the Princess Takamatsu Cancer Resarch Fund covered advances in chemical carcinogenesis and cancer chemotherapy. It notes that humans are continuously exposed to carcinogens, so the amount of carcinogenic xenobiotics and the human response to them is important.

Author: National Library of Medicine (U.S.)
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1332

View

Book Description

Author: M.P. Manns
Publisher: Springer Science & Business Media
ISBN: 9401140006
Category : Medical
Languages : en
Pages : 426

View

Book Description
In 1992, the Falk Symposium No. 70 dealt with the topic `Immunology and Liver'. At that time basic mechanisms of immunology as well as immunopathogenetic mechanisms in viral and autoimmune liver diseases were discussed. Now, 7 years later, the Falk Symposium No. 114, held in Basel, Switzerland, October 20-21 1999 (Part I of the Basel Liver Week 1999), focused on immunology in autoimmune liver diseases. In the first section basic mechanisms of autoimmunity are presented, including the relevance of superantigens and the role of apoptosis. A further topic is the latest developments concerning animal models for autoimmune diseases. Recently the International Autoimmune Hepatitis Group newly defined and reclassified the syndrome of autoimmune hepatitis. Autoimmune hepatitis is now identified and studied in all parts of the world, including Asia and South America. A special variant of autoimmune hepatitis was identified as one organ manifestation of the autoimmune polyendocrine syndrome type 1, a genetic disease caused by mutations in a single transcription factor. Drug- and hepatitis-virus induced immune mediated liver diseases may serve as models for nonhepatic immune mediated disorders. DNA technology has increased our knowledge of the immunogenetic background of autoimmune liver diseases. Among the cholestatic immune mediated liver diseases, significant progress has been made concerning primary biliary cirrhosis, in particular regarding the identification of mitochondrial antigens and the characterisation of the immune reactions directed at them. The involvement of infectious agents in PBC as well as the definition of overlap syndromes is a particular focus for basic and clinical research in this area. Concerning the therapy of autoimmune liver diseases, corticosteroids and azathioprin remain the state of the art for autoimmune hepatitis, while bile acids have become well established in treatment of primary biliary cirrhosis as well as primary sclerosing cholangitis. New drugs in the future will include topical steroids such as budesonide and new immunosuppressive agents like mofetil/mycophenolate. Liver transplantation is the treatment of choice for end stage liver diseases; all autoimmune liver diseases are among the best candidates for liver transplantation. Hopefully, new therapeutic strategies based on the results obtained from experimental models will become everyday clinical practice in the next decade. Therefore this symposium concludes with a discussion.

Author: W. Scheppach
Publisher: Springer Science & Business Media
ISBN: 9780792387800
Category : Medical
Languages : en
Pages : 698

View

Book Description
This book is the proceedings of Falk Symposium 128, held in Würzburg, Germany, on May 2-3, 2002, and dedicated to the important issue of colonic carcinogenesis and its underlying genetic and environmental factors. Colorectal cancer is one of the leading causes of cancer-related death in industrialized countries. It has been recognized to be the consequence of a dynamic process leading from hyperproliferative epithelium through different classes of adenomas to invasive carcinoma. This adenoma-carcinoma sequence has been characterized on a molecular basis. Modern molecular biology has also helped to clarify the clustering of colorectal cancer within families, a phenomenon that has been known to clinicians for a long time. Thus, the pathogenesis of the two distinct familial colon cancer syndromes FAP (familial adenomatous polyposis) and HNPCC (hereditary non-polyposis colorectal cancer) is increasingly being understood. Thereby, an identification of affected people has become possible before the disease has manifested. There is also convincing evidence that the pathogenesis of sporadic colonic cancer is modulated by environmental, mainly nutritional, factors. Carcinogens seem to be far less important than the components of the `normal' human diet. It is likely that the interplay between protective and noxious dietary compounds determines the progression of the adenoma-carcinoma sequence. Additionally, a broad spectrum of drugs has been shown to affect colonic tumorigenesis, which provides the rationale for chemoprevention strategies. These issues set the scene for discussions on how genetic and environmental factors may interact in the pathogenesis of colonic cancer, contributing fresh ideas to the prevention of this most prevalent malignancy in the industrialized world.

Author: National Cancer Institute (U.S.). Division of Cancer Etiology
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 538

View

Book Description